The drug in Ozempic extended healthy mice’s lives by nearly 100 days — in a trial that had nothing to do with weight

For a drug best known for trimming waistlines, semaglutide has been accumulating a second résumé. A new Nature paper from the University of California, Berkeley, reports that the compound — the active ingredient in Ozempic and Wegovy — extended the median lifespan of healthy female mice by nearly 100 days. The mice were not overweight. They were not diabetic. Their metabolic rate barely changed. Whatever pathway semaglutide used to add nearly three months to their lives, it was not the one most people assume.

The study, led by Danica Chen, Ph.D., and funded by the National Institutes of Health, started with 20-month-old female mice — the equivalent of a middle-aged adult approaching old age. That age was deliberate. The researchers wanted to test whether a GLP-1 receptor agonist could intervene late in the lifespan, after the usual windows for dietary and metabolic optimization had largely closed.

The results landed in a journal that does not publish incremental work. And they raised a question that the weight-loss framing of GLP-1 drugs has so far kept in the background: what is semaglutide actually doing to the biology of aging?

How the Berkeley team designed the experiment

The mice received semaglutide for three months, administered during the period when the cohort was already in late middle age. A subset was followed through to the natural end of their lives. A control group received no treatment. A third group was placed on calorie restriction — a reduction in food intake that has been the most reliable method for extending rodent lifespans since its first demonstration in the 1930s.

Calorie restriction was the benchmark against which everything else was measured. It has extended lifespan in almost every organism studied, from yeast to rhesus monkeys, by slowing metabolism and reducing the cellular damage that accumulates with energy expenditure. If semaglutide was going to be taken seriously as a longevity intervention, it needed to survive the comparison.

What the data showed

The treated females lived a median of nearly 100 days longer than untreated controls. That number is not a rounding artifact — it represents a meaningful fraction of a mouse’s natural lifespan, which typically runs 24 to 30 months.

But the comparison with calorie restriction was the finding that sharpened the paper’s argument. Semaglutide-treated mice outperformed their calorie-restricted counterparts on two measures that calorie restriction has historically been good at: spatial memory and blood-sugar control. On exploratory behavior tests, semaglutide mice were also more active and engaged than the restricted group.

Critically, the metabolic rate of semaglutide-treated animals remained largely unchanged — a contrast with calorie restriction, which reduces metabolic rate as part of its mechanism. The two interventions were producing similar longevity outcomes through different biological routes.

What the gene expression revealed

The researchers did not stop at lifespan and behavior. They analyzed gene expression in the treated animals and found patterns consistent with reduced biological aging: lower markers of inflammatory activity, and improved regenerative capacity in tissues that tend to decline with age.

Inflammation is a well-established driver of aging-related disease. Chronic low-grade inflammation — sometimes called inflammaging — accumulates over time and contributes to cardiovascular disease, neurodegeneration, and metabolic dysfunction. The gene-expression signature in semaglutide-treated mice suggested the drug was suppressing this process through a pathway that does not require the animal to eat less.

National Institute on Aging researcher Rafael de Cabo, Ph.D., who provided commentary on the paper, described the findings as evidence that GLP-1 receptor agonists tap into a biological pathway independent of calorie restriction. That characterization matters: it means the drug is not simply mimicking dietary deprivation at the molecular level. It is doing something structurally different.

The part the data cannot yet answer

The study was conducted exclusively on female mice. No male data is reported. That is not an oversight — sex-specific effects in longevity research are well documented, and designing a study around a single sex allows cleaner mechanistic analysis — but it means the finding cannot yet be generalized even within the mouse model.

The treated group comprised 20 animals. That sample size is standard for this type of mechanistic longevity study, but it limits the statistical confidence that can be assigned to any individual endpoint. The lifespan extension is robust enough to report; the finer-grained cognitive and metabolic comparisons carry more uncertainty.

The most important limitation is the one that applies to every rodent longevity study: mice are not humans. GLP-1 receptors exist in human brains, and semaglutide does cross the blood-brain barrier in measurable quantities. But the pathway from a rodent lifespan result to a human clinical claim has broken down before. Rapamycin extends mouse lifespan reliably and has done so across many independent studies; its translation to human longevity remains unresolved after two decades of investigation. Resveratrol followed the same arc. Metformin is still in clinical trials. The history of longevity research in model organisms includes many findings that did not survive the species boundary.

Common questions about semaglutide and longevity

What is semaglutide and why is this study significant?

Semaglutide is a GLP-1 receptor agonist, a class of drugs originally developed to manage blood sugar in type 2 diabetes and later approved for weight loss under brands including Ozempic, Wegovy, and Rybelsus. This Nature study is significant because it demonstrates a lifespan-extending effect in healthy, non-obese animals — suggesting the drug’s biology goes beyond appetite and glucose regulation.

Does this mean semaglutide extends human lifespans?

The study was conducted in mice, and lifespan effects in rodents have frequently failed to translate to humans. No clinical evidence currently supports using semaglutide as a longevity drug in people. The finding opens a hypothesis to test, not a conclusion to act on.

Why were only female mice studied?

Sex-specific longevity effects are common in model organisms, and studying a single sex allows cleaner detection of mechanistic signals. Male mice will likely be studied in follow-up work. Until those results exist, the lifespan-extension finding applies only to the female animals in this cohort.

How does this compare to calorie restriction as a longevity strategy?

Calorie restriction extends lifespan in rodents by slowing metabolic rate and reducing cumulative cellular damage. Semaglutide produced comparable lifespan extension through a different pathway — metabolic rate was largely unchanged — and outperformed calorie restriction on spatial memory and blood-sugar control. The two approaches appear to work independently.

What do the researchers plan to study next?

Immediate next steps include testing the effect in male mice and identifying the specific molecular mechanism through which semaglutide’s GLP-1 signaling intersects with aging pathways. Human translation is a longer-term question that would require dedicated clinical trial design.

What the finding positions semaglutide to become

The GLP-1 drug class was approved for a narrow indication and expanded rapidly because the clinical data kept arriving in places researchers had not expected. Cardiac protection in diabetic patients appeared first. Then neurological signals — lower rates of cognitive decline in some observational datasets. Now a peer-reviewed lifespan extension in a healthy animal model, from a laboratory with strong credentials in aging biology.

The pattern does not prove that semaglutide is an aging drug. It raises the question seriously enough that the question now needs to be asked formally. Danica Chen’s team has handed the longevity research field a mechanistic thread to pull — one that runs through a drug that 50 million people are already taking for other reasons.

Tags: nature, longevity, aging, calorie restriction, GLP-1, Ozempic